As the year comes to a close, CHI-Dignity are poised to create a mega health system. Meanwhile, in D.C., budget drama unfolds like a reality T.V. show.
A Kentucky appeals court says the secret testimony from a former president of one of the world's largest manufacturers of dangerously addictive opioid painkillers must be released to the public.
Federal and Massachusetts authorities allege Minneapolis-based Target violated federal and state False Claims Acts by automatically refilling Medicaid recipients' prescriptions and seeking payment from Medicaid.
RTX, which is derived from a flowering cactuslike plant native to Morocco known as Euphorbia resinifera or resin spurge, is not only fiery, it's accurate. It can target and destroy nerve endings for pain, and for pain only.
Although system CEOs see some benefits to the change of control in the House, the likelihood of partisan gridlock is muting their optimism.
Generic-drug maker Sandoz will start selling an alternative to the EpiPen in the U.S. early next year. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems.
Of the 148 applications the GAO analyzed, reviewers granted orphan status to 26 that were missing required information.
Nearly 1 in 4 chronic opioid users in Idaho were at risk of overdosing due to unsafe prescription combinations in 2017, and a study questions whether efforts to improve prescribing practices are working.
Drug industry insiders are questioning whether Sen. Bernie Sanders' proposal to cut pharma patent protections if drug prices are too high will ultimately limit access to new therapies.
Independent pharmacists in New York are calling for a state investigation into the practices of pharmacy benefit managers—the companies that negotiate drug prices on behalf of insurers and employers. They blame the PBMs for forcing owners to close up shop.
In 2017, brand-name prescription drugs made up only 17% of total prescriptions filled but represented 79% of total drug spending, according to an updated study from the Blue Cross and Blue Shield Association.
The FDA on Nov. 2 approved a new super-potent opioid tablet for use in hospitals. While prescribing numbers for opioids have been declining for the past few years, prescription use of painkillers still present a major challenge for combating the overall opioid crisis.